

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ELI LILLY AND COMPANY,  
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,  
Patent Owner.

---

Case IPR2018-01710 (Patent 8,586,045 B2)  
Case IPR2018-01711 (Patent 8,884,907 B2)  
Case IPR2018-01712 (Patent 8,884,908 B2)<sup>1</sup>

---

**PATENT OWNER'S DEMONSTRATIVES**

---

<sup>1</sup> A word-for-word identical copy of this paper is filed in each proceeding identified in the caption.



2018-01710\*  
2018-01711  
2018-01712



---

Eli Lilly and Company  
v.  
Teva Pharmaceuticals International GmbH

---

January 8, 2020

(\* - unless otherwise indicated, all citations to papers refer to IPR2018-01710)

## A POSA would not have had a reason to treat migraine with anti-CGRP antibodies with a reasonable expectation of success

### A POSA would not have extended Olesen's small-molecule receptor "CGRP antagonists" to anti-CGRP ligand antibodies

- Olesen: The **CGRP antagonist BIBN 4096 BS** was effective in treating acute attacks of migraine. EX1025, Abstract
- Dr. Ferrari: "A POSA reviewing Olesen would not have drawn a conclusion that clinical trials using BIBN4096BS would translate broadly to all 'CGRP antagonism' being effective in treating migraine." EX2268, ¶98; EX1040, 182; EX2265, 60-62; POR, 12-13, Surreply, 6

### Tan's full-length antibody did not achieve immunoblockade

- "only the Fab' fragment was found to be an effective tool for blockade " in rats. EX1022, 570; POR, 39; EX2054, ¶51.

### Active research of anti-CGRP antibodies stopped with Tan

- In the decade between Tan and Teva's invention, multiple companies developed small-molecule, short half-life, receptor antagonists. POR 8-9, EX2268, ¶152; EX2014, Abstract; EX2071, Abstract; EX2009, 617; EX2003, 910; EX2009, 617; EX2012, 769; EX2015; EX2016.

### A POSA would not have reasonably expected an anti-CGRP antibody to successfully treat migraine

POR, 3-4, 8, 19-20, 35-36, 38-42, 45-47; Surreply, 17-25; EX2265, ¶¶60-68, 88-90, 134; EX1022, 565-566, 571, Abstract; EX2268, ¶¶25-38, 42, 56-57, 75, 88-90; EX2191, 118:12-119:1; EX1096, 567; EX2161, 6; EX2336, 34:12-16; 80:19-81:7, 98:14-99:17; EX2335, 1; EX2306; EX2291, 4; EX2296, 1452; EX2222, Abstract; EX2223, 2; EX2277, 101:15-102:1; EX2310, 5881; EX2223, 2; EX2306, 789; EX2337, 64:10-65:5; EX2339, 93:19-95:6; 95:10-12;

**Lilly's invention led to breakthrough migraine therapy** POR, 7, 32, 56-59; Surreply, 27-29

**Lilly admits that Emgality satisfied a long-felt, unmet need:**

- “[A] Lilly co-authored publication acknowledged that humanized anti-CGRP antibodies were a ‘[s]afe, effective and well tolerated treatment for the prevention of migraine’ that satisfied this ‘enormous unmet medical need.’” POR, 59, EX2161, 890; EX2262, ¶140
  - “LY2951742 was effective and generally well tolerated for the preventive treatment of migraine in patients with frequent attacks.” EX2161, 890
  - “Safe, effective, and well tolerated treatment for the prevention of migraine represents an enormous unmet medical need.” EX2161, 890

**The Industry praised the claimed methods of treatment:**

- “an enormous step forward” EX2172, 1-2; POR, 56-58; EX2260, ¶154
- “a game changer” EX2179, 4; POR, 56-58; EX2262, ¶156
- a “breakthrough in migraine” EX2174, 707; POR, 56-58; EX2262, ¶153

**Lilly's expert, Dr. Charles, also praised the claimed methods of treatment as:**

- “radical concept” EX2053, 23; POR, 7, 32; EX2262, ¶161
- “very exciting and compelling” EX2182, 207; POR, 56; EX2262, ¶161
- “absolutely life-changing” EX2186, 4; POR, 56; EX2262, ¶161
- “spectacular” EX2186, 4-5; POR, 56; EX2262, ¶161

## Skepticism surrounded development of anti-CGRP antibodies for treating migraine

POR, 61-62; Surreply, 28

### Inventor Jaime Pons:

- “Key Opinion Leaders (“KOL”) frequently expressed **skepticism** that an antibody like fremanezumab would be able to **treat migraine** because it could not cross the BBB. EX2331, ¶16
- “Pfizer expressed the same **concerns** over fremanezumab’s ability to **treat migraine** due to its inability to enter the CNS.” EX2331, ¶17
- “After Pfizer acquired Rinat, work on RN307 [fremanezumab] was halted for several years because Pfizer **did not think** that the molecule would **treat migraine**.” EX2331, ¶18
- “Several of the [venture capital firms] expressed **skepticism** that **treatment of migraine** was possible with a drug that could not enter the CNS.” EX2331, ¶111

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.